Skip to main content

Australian prescription medicine decision summaries

These decision summaries provide an overview of our evaluation process leading to the registration of a new prescription medicine.

For more information please visit the Australian prescription medicine decision summaries information page. 

Use the filters below to narrow your search.

Filter results

You can narrow down the results using the filters.


202 result(s) found, displaying 1 to 25
  • Spy Agent Green

    Australian Prescription Medicine Decision Summary
  • Onakta

    Australian Prescription Medicine Decision Summary
  • Veoza

    Australian Prescription Medicine Decision Summary
  • Erwinase

    Australian Prescription Medicine Decision Summary
  • Onbevzi

    Australian Prescription Medicine Decision Summary
  • Wezlana

    Australian Prescription Medicine Decision Summary
  • Arexvy

    Arexvy (recombinant respiratory syncytial virus pre-fusion F protein) is approved for individuals 60 years and older for the prevention of lower respiratory tract disease caused by respiratory syncytial virus
  • Raniviz

    Raniviz (ranibizumab) is approved to treat visual impairment issues.
  • Aquipta

    Aquipta (atogepant) is approved for prophylaxis of migraine in adults
  • Givlaari

    Givlaari (givosiran) is approved to treat acute hepatic porphyria.
  • Sohonos

    Sohonos (palovarotene) is approved to reduce the formation of heterotopic ossification.
  • Beyfortus

    Beyfortus (nirsevimab) is approved for the prevention of respiratory syncytial virus (RSV) in neonates, infants and vulnerable children up to the age of 24 months.
  • Spevigo

    Spevigo (spesolimab) is approved for the treatment of flares in adult patients with generalised pustular psoriasis.
  • Heparin Interpharma

    Heparin Interpharma (heparin sodium) is approved for prophylaxis and treatment of deep vein thrombosis in patients 18 years and older.
  • Vafseo

    Vafseo (vadadustat) is approved to treat anaemia associated with chronic kidney disease in adults on chronic maintenance dialysis.
  • Omvoh

    Omvoh (mirikizumab) is approved to treat moderately to severely active ulcerative colitis.
  • Alhemo

    Alhemo (concizumab) is approved to prevent haemophilia.
  • Tibsovo

    Tibsovo (ivosidenib) is approved to treat acute myeloid leukaemia that carries an IDH1 R132 mutation.
  • Vaxchora

    Vaxchora (vibrio cholerae) is approved to prevent disease caused by Vibrio cholerae serogroup O1 in those travelling to cholera-affected countries.
  • Vegzelma

    Vegzelma (bevacizumab) is approved to treat cancer.
  • Xenpozyme

    Xenpozyme (olipudase alfa) is approved for the treatment of non-central nervous system (CNS) manifestations of acid sphingomyelinase deficiency (ASMD).
  • Columvi

    Columvi (glofitamab) is provisionally approved to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
  • Nurtec ODT

    Nurtec ODT (rimegepant (as sulfate)) is approved to treat migraine
  • Exarane/Exarane Forte

    Exarane (enoxaparin sodium) is approved to prevent and/or treat thromboembolic disorders, angina and non-Q-wave myocardial infarction and ST-segment Elevation Myocardial Infarction.
  • Tavneos

    TGA decision: Tavneos (avacopan) is approved to treat adults with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]).

Help us improve the Therapeutic Goods Administration site